Search the Newsreel

McCoy Global: CFO Lindsay McGill Intends to Commence a Planned Maternity Leave of Absence in 4Q of 2026 >MCB.T

Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Coya Therapeutics Inc (COYA) has an earnings forecast score of 8.33, ranking 138th in its industry. Analysts have set an average price target of $16.00 for COYA, with most supporting a "Buy" trend. The company's expected revenue for the next quarter is $100,000, and …

Analysts Are Bullish on These Healthcare Stocks: Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE)

This article highlights bullish analyst ratings for several healthcare stocks, including Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE), and SI-Bone (SIBN). Analysts from Chardan Capital and TD Cowen reiterated Buy ratings for these companies, providing specific price targets and noting potential upsides. The report …

McCoy Global’s 4.59% Yield Faces a Reality Check After Dividend Pause

Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday

Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis

Coya Therapeutics Inc (COYA) has a current financial score of 6.42, placing it 245th out of 384 in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 2.61% year-over-year to 251.15K, …

Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis

Coya Therapeutics Inc (COYA) has a current valuation score of 6.86, placing it 248th out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.64, which is significantly below its recent high and above its recent low. Key …

McCoy Global Stock Climbs 2.80%: Energy Equipment Demand and Industrial Automation Strengthen Investor Confidence

Coya Therapeutics Inc (COYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Coya Therapeutics Inc (COYA), focusing on its stock price momentum, support and resistance levels, and key technical indicators and moving averages. As of July 28, 2026, Coya Therapeutics Inc's stock price momentum score is 5.14, ranking 119 …

COYA|Coya Therapeutics Inc|Price:4.015|Chg%:-0.250

This article provides a detailed stock analysis of Coya Therapeutics Inc (COYA) by TradingKey, assigning it a comprehensive stock score based on various financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment indicators. Despite a recent weak stock market performance, COYA …

McCoy Global (TSX:MCB) Sees Revenue Cut in Half — Net Cash Flips to Net Debt

Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing

Orin Hirschman and affiliated investment entities, including AIGH Capital Management LLC and AIGH Investment Partners LLC, have filed an amended Schedule 13G disclosing a 3.3% beneficial ownership stake in Coya Therapeutics Inc. (NASDAQ: COYA). This represents 764,679 shares of common stock, over which they …

Coya Therapeutics Inc (COYA) Cash Flow

This article provides a detailed cash flow statement for Coya Therapeutics Inc (COYA), presenting quarterly and annual data for operating, investing, and financing activities. It includes year-over-year percentage changes and absolute figures for various cash flow components. Additionally, the article offers FAQs explaining key …

Coya Therapeutics Inc Today's Market Trends | COYA Stock Real-Time Quotes, Trading Strategies & Related Analysis

Coya Therapeutics Inc (COYA) is a clinical-stage biotechnology company developing treatments targeting systemic inflammation and neuroinflammation using regulatory T cells. Despite a recent weak market performance, the company exhibits strong fundamentals, including consistent revenue growth averaging 32.38% annually over the last three years and …

Coya Therapeutics Market Sentiment

This article provides an overview of Coya Therapeutics (COYA) market sentiment, including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly higher than the current stock price. Short interest is declining, considered a …

Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of "Moderate Buy" from Analysts

Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Coya Therapeutics Inc (COYA), listing major shareholders such as Greenlight Capital, Inc. and Dr Reddy's Laboratories Ltd, along with their respective proportions. It also categorizes shareholders by type and provides a historical overview of institutional shareholding changes. …

Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Coya Therapeutics Inc (COYA). It states that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock …

Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA

Coya Therapeutics, Inc. (NASDAQ:COYA) reported a total revenue of $7.95 million USD last year. This revenue primarily came from its Proprietary Medicinal Products segment, marking an increase from $3.55 million USD in the prior year. The United States was the sole contributor to this …

Coya Therapeutics (NASDAQ:COYA) Trading Up 0.2% - Should You Buy?

Coppermoly (ASX:COY) Expands Portfolio With Wyemandoo Critical Minerals Acquisition

Discipline and Rules-Based Execution in COYA Response

This article from Stock Traders Daily discusses the application of discipline and rules-based execution for COYA Therapeutics Inc. (NASDAQ: COYA) using AI models. It highlights three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The content emphasizes real-time signals, risk …

Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA

This article provides the "Price to book forward" value for Coya Therapeutics, Inc. (NASDAQ: COYA). While the specific value is not detailed in the provided content, the article indicates that this financial metric is available for the company on TradingView. It also lists various …

Houston ALS Biotech Coya Eyes 2028 Approval Path

Coya Therapeutics, a Houston-based biotech, is advancing its lead candidate COYA 302 for ALS, with a pivotal Phase 2 trial readout expected in early 2027 and potential conditional approval by the first half of 2028. The company is supported by strong analyst ratings and …

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

Coya Therapeutics (COYA) is a clinical-stage biopharma company focusing on treatments for ALS and dementia, with multiple analysts giving "Buy" ratings and price targets up to US$18. The company anticipates a significant trial readout in Q1 2027 for its ALS drug, COYA 302, with …

McCOY GLOBAL ANNOUNCES FIRST QUARTER 2026 RESULTS

MCCOY GLOBAL ANNOUNCES SUCCESSFUL CLOSE OF US$10.0 MILLION CREDIT FACILITY

MCCOY GLOBAL ANNOUNCES FOURTH QUARTER AND YEAR END 2025 RESULTS AND IN RESPONSE TO IMPACTS OF THE RECENT MIDDLE EAST CONFLICT PAUSES QUARTERLY DIVIDEND

McCoy Global (TSE:MCB) Might Have The Makings Of A Multi-Bagger

Decoy Therapeutics Inc (DCOY) Stock Price, Quote, News & History

Coppermoly Limited (ASX:COY) - Shares, Dividends & News